Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

NCT06334133 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG: Cadisegliatin 800 mg QD
DRUG: Cadisegliatin 800 mg BID
DRUG: Placebo

Sponsor

vTv Therapeutics